Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin

被引：26

作者：

Chevallier, P. ^{[1
,2
]}

Prebet, T. ^{[3
]}

Pigneux, A. ^{[4
]}

Hunault, M. ^{[5
]}

Delaunay, J. ^{[1
,2
]}

Perry, F. ^{[4
]}

Lode, L. ^{[1
,2
]}

Richebourg, S. ^{[1
,2
]}

Blanchet, O. ^{[5
]}

Vey, N. ^{[3
]}

Ifrah, N. ^{[5
]}

Milpied, N. ^{[4
]}

Blaise, D. ^{[3
]}

Harousseau, J-L ^{[1
,2
]}

Mohty, M. ^{[1
,2
]}

机构：

[1] CHU Nantes, Serv Hematol Clin, F-44035 Nantes 01, France

[2] Univ Nantes, INSERM, U892, Nantes, France

[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[4] CHU Bordeaux, Serv Hematol Clin, Bordeaux, France

[5] CHU Angers, Serv Hematol Clin, Angers, France

来源：

LEUKEMIA | 2010年 / 24卷 / 02期

关键词：

ACUTE MYELOID-LEUKEMIA; MUTATIONS; DISEASE; PROGNOSIS;

D O I：

10.1038/leu.2009.214

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：467 / 469

页数：3

共 8 条

[1] Interactive diagnostics in the indication to allogeneic SCT in AML [J].

Bacher, U. ;

Haferlach, C. ;

Schnittger, S. ;

Kern, W. ;

Kroeger, N. ;

Zander, A. R. ;

Haferlach, T. .

BONE MARROW TRANSPLANTATION, 2009, 43 (10) :745-756

[2] Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia [J].

Chevallier, Patrice ;

Delaunay, Jacques ;

Turlure, Pascal ;

Pigneux, Arnaud ;

Hunault, Mathilde ;

Garand, Richard ;

Guillaume, Thierry ;

Avet-Loiseau, Herve ;

Dmytruk, Nathalia ;

Girault, Stephane ;

Milpied, Noel ;

Ifrah, Norbert ;

Mohty, Mohamad ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5192-5197

[3] Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability [J].

Meloni, Giovanna ;

Mancini, Marco ;

Gianfelici, Valentina ;

Martelli, Maria Paola ;

Foa, Robin ;

Falini, Brunangelo .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (02) :298-300

[4] Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation [J].

Metzelder, Stephan ;

Wang, Ying ;

Wollmer, Ellen ;

Wanzel, Michael ;

Teichler, Sabine ;

Chaturvedi, Anuhar ;

Eilers, Martin ;

Enghofer, Erich ;

Neubauer, Andreas ;

Burchert, Andreas .

BLOOD, 2009, 113 (26) :6567-6571

[5] NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia [J].

Palmisano, Michela ;

Grafone, Tiziana ;

Ottaviani, Emanuela ;

Testoni, Nicoletta ;

Baccarani, Michele ;

Martinelli, Giovanni .

HAEMATOLOGICA, 2007, 92 (09) :1268-1269

[6] Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia [J].

Schlenk, Richard F. ;

Doehner, Konstanze ;

Krauter, Juergen ;

Froehling, Stefan ;

Corbacioglu, Andrea ;

Bullinger, Lars ;

Habdank, Marianne ;

Spaeth, Daniela ;

Morgan, Michael ;

Benner, Axel ;

Schlegelberger, Brigitte ;

Heil, Gerhard ;

Ganser, Arnold ;

Doehner, Hartmut .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) :1909-1918

[7] Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype [J].

Schnittger, S ;

Schoch, C ;

Kern, W ;

Mecucci, C ;

Tschulik, C ;

Martelli, MF ;

Haferlach, T ;

Hiddemann, W ;

Falini, B .

BLOOD, 2005, 106 (12) :3733-3739

[8] Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease [J].

Schnittger, S ;

Schoch, C ;

Dugas, M ;

Kern, W ;

Staib, P ;

Wuchter, C ;

Löffler, H ;

Sauerland, CM ;

Serve, H ;

Büchner, T ;

Haferlach, T ;

Hiddemann, W .

BLOOD, 2002, 100 (01) :59-66

← 1 →